Cargando…

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

Concerns have been raised regarding an increased risk of major adverse cardiovascular events (MACEs) (myocardial infarction, cerebrovascular accident or cardiovascular death) in patients treated with anti‐interleukin (IL)‐12/23 agents for moderate‐to‐severe psoriasis. We aimed to examine the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rungapiromnan, W., Yiu, Z.Z.N., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412670/ https://www.ncbi.nlm.nih.gov/pubmed/27518205 http://dx.doi.org/10.1111/bjd.14964

Ejemplares similares

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Z.Z.N., et al.
Publicado: (2018)

Risk of COVID‐19 infection in adult patients with atopic eczema and psoriasis: a single‐centre cross‐sectional study
por: Yiu, Z.Z.N., et al.
Publicado: (2021)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
por: Mason, K.J., et al.
Publicado: (2019)

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
por: Al‐Janabi, A., et al.
Publicado: (2021)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley, Tessa, et al.
Publicado: (2016)

Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational Studies
por: Armstrong, Ehrin J., et al.
Publicado: (2013)

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
por: Thorneloe, R.J., et al.
Publicado: (2016)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

The global state of psoriasis disease epidemiology: a workshop report
por: Griffiths, C.E.M., et al.
Publicado: (2017)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study
por: Springate, D.A., et al.
Publicado: (2016)

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
por: Caiazzo, Giuseppina, et al.
Publicado: (2018)

How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials
por: Nartowicz, Sonia, et al.
Publicado: (2021)

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
por: Warren, RB, et al.
Publicado: (2009)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022)

Heterogeneous plaque–lumen geometry is associated with major adverse cardiovascular events
por: Gu, Sophie Z, et al.
Publicado: (2023)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
por: Warren, R.B., et al.
Publicado: (2018)

Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
por: Champs, Bénédicte, et al.
Publicado: (2019)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
por: Kristensen, Lars E., et al.
Publicado: (2023)

The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study
por: Hong, Joo Ran, et al.
Publicado: (2021)

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
por: Jabbar-Lopez, Zarif K., et al.
Publicado: (2017)

Fertility Trends and Adverse Pregnancy Outcomes in Female Patients With Psoriasis in the UK
por: Chen, Teng-Chou, et al.
Publicado: (2023)

Giant condylomata acuminata of Buschke and Lowenstein: A peristomal variant
por: Yiu, Z.Z.N., et al.
Publicado: (2014)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
por: Peluso, Rosario, et al.
Publicado: (2018)

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
por: Yiu, Zenas Z. N., et al.
Publicado: (2020)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aca70p274tr6kj3v3e2psj861p